Kezar bags a $50M B round in wake of PhIa study; Bay­er kicks back a part­nered drug

→ Right on the heels of what it calls a suc­cess­ful Phase Ia study for its im­muno­pro­tea­some in­hibitor, South San Fran­cis­co-based Kezar Life Sci­ences has at­tract­ed a big syn­di­cate for a $50 mil­lion B round. Cor­morant As­set Man­age­ment and Morn­ing­side Ven­ture led the round, which in­cludes new in­vestors like Cowen Health­care In­vest­ments, Pap­pas Ven­tures, Qim­ing Ven­ture Part­ners and Bay City Cap­i­tal. They were joined by ex­ist­ing in­vestors EcoR1 Cap­i­tal, Omega Funds, and Aju IB In­vest­ment. Kezar has now raised a to­tal of $73 mil­lion since its in­cep­tion in 2015.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.